Strategic partnerships AC Immune has a history of securing strategic partnerships with leading global pharmaceutical companies, delivering substantial non-dilutive funding and potential milestone payments. This suggests strong collaboration appeal for BD outreach focused on co-development, licensing, or milestone-driven deals.

Diverse pipeline With sixteen therapeutic and diagnostic programs across neurodegenerative diseases and multiple assets in Phase 2 and Phase 3, there are multiple entry points for partnerships, including co-development, out-licensing, and platform-based collaborations across SupraAntigen and Morphomer.

Technology leverage Two validated platforms SupraAntigen and Morphomer enable precision prevention approaches; targeting misfolded proteins and intrabody strategies open opportunities for tech-driven collaborations with diagnostic imaging, biomarker development, and targeted therapeutics.

Financial runway Existing funding of 171M and revenue in the tens of millions provide a relatively stable financial foundation for potential deal structures, including upfronts, milestone-rich arrangements, and funded research collaborations that mitigate early-stage risk for partners.

Leadership transition Recent leadership changes including the retirement of the CEO may open conversations about strategic refocus, advisory partnerships, or co-investment opportunities as the company pivots its clinical agenda and pipeline partnerships.